Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
ZVSA 
ZyVersa Therapeutics Inc. (ZVSA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/05/2025: ZVSA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $20
1 Year Target Price $20
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -71.21% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.13M USD | Price to earnings Ratio - | 1Y Target Price 20 |
Price to earnings Ratio - | 1Y Target Price 20 | ||
Volume (30-day avg) 1 | Beta 0.81 | 52 Weeks Range 0.11 - 1.95 | Updated Date 12/6/2025 |
52 Weeks Range 0.11 - 1.95 | Updated Date 12/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.32 |
Earnings Date
Report Date 2025-11-13 | When Before Market | Estimate -0.25 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -46.3% | Return on Equity (TTM) -112.65% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -1995589 | Price to Sales(TTM) - |
Enterprise Value -1995589 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.21 | Shares Outstanding 8095921 | Shares Floating 7677524 |
Shares Outstanding 8095921 | Shares Floating 7677524 | ||
Percent Insiders 0.03 | Percent Institutions 5.15 |
Upturn AI SWOT
ZyVersa Therapeutics Inc.
Company Overview
History and Background
ZyVersa Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for inflammatory and autoimmune diseases. The company has evolved through various stages of research and development, aiming to bring innovative treatments to patients with unmet medical needs. Significant milestones would include the progression of its drug candidates through preclinical and clinical trials.
Core Business Areas
- Drug Development: ZyVersa Therapeutics Inc. is primarily engaged in the research, development, and potential commercialization of small molecule therapeutics. Their focus is on addressing diseases characterized by inflammation and immune system dysregulation.
Leadership and Structure
The leadership team typically comprises individuals with expertise in drug development, clinical research, regulatory affairs, and business management. The organizational structure is characteristic of a biopharmaceutical company, with departments dedicated to R&D, clinical operations, business development, and finance.
Top Products and Market Share
Key Offerings
- Vac Nix: A novel small molecule drug candidate aimed at treating inflammatory diseases. The specific market share for such an early-stage drug is not applicable. Competitors would include companies developing similar anti-inflammatory agents or biologics targeting specific inflammatory pathways.
- IC 100: Another therapeutic candidate in their pipeline, also focused on inflammatory conditions. Market share data is not available at this stage. Competitors are broad, encompassing various pharmaceutical and biotech companies with anti-inflammatory drug portfolios.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly the segment focused on inflammatory and autoimmune diseases, is highly competitive and innovation-driven. It is characterized by significant investment in R&D, complex regulatory pathways, and a constant need for novel therapeutic approaches.
Positioning
ZyVersa Therapeutics Inc. positions itself as a developer of innovative, small molecule therapies for diseases with significant unmet needs. Their competitive advantage lies in their proprietary science and the potential of their drug candidates to offer improved efficacy or safety profiles compared to existing treatments.
Total Addressable Market (TAM)
The Total Addressable Market for inflammatory and autoimmune diseases is vast, spanning billions of dollars globally. ZyVersa Therapeutics Inc. aims to capture a portion of this market with its targeted therapies. Their current positioning is early-stage, focusing on developing and proving the efficacy of their lead candidates.
Upturn SWOT Analysis
Strengths
- Novel drug candidates with potential for differentiation
- Experienced management and scientific team
- Focus on significant unmet medical needs
Weaknesses
- Clinical-stage company, meaning significant risk and uncertainty in drug development
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on successful clinical trial outcomes and regulatory approvals
Opportunities
- Growing market for treatments of inflammatory and autoimmune diseases
- Potential for strategic partnerships and collaborations
- Advancements in biotechnology and drug discovery
Threats
- Failure in clinical trials
- Regulatory hurdles and delays
- Intense competition from established and emerging biopharmaceutical companies
- Patent expirations and generic competition for other treatments
Competitors and Market Share
Key Competitors
- AbbVie Inc. (ABBV)
- Janssen Biotech, Inc. (subsidiary of Johnson & Johnson - JNJ)
- Eli Lilly and Company (LLY)
- Pfizer Inc. (PFE)
- Bristol Myers Squibb Company (BMY)
Competitive Landscape
ZyVersa Therapeutics Inc. faces a highly competitive landscape dominated by large, established pharmaceutical companies with extensive R&D budgets and commercial infrastructure. Their advantage lies in potentially developing novel mechanisms of action or addressing specific patient populations with unmet needs. Their disadvantage is their smaller size, limited resources, and higher risk profile associated with early-stage drug development.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by equity financing to fund its research and development pipeline. The company's growth is measured by the progression of its drug candidates through clinical trials.
Future Projections: Future growth is contingent upon successful clinical trial outcomes, regulatory approvals, and eventual commercialization of its therapeutic candidates. Analyst projections, if available, would focus on potential peak sales of its lead products.
Recent Initiatives: Recent initiatives likely involve advancing its lead drug candidates (Vac Nix and IC 100) into or through clinical trials, securing funding, and building strategic partnerships.
Summary
ZyVersa Therapeutics Inc. is a biopharmaceutical company with promising drug candidates for inflammatory diseases. Its strengths lie in its novel science and experienced team. However, it faces significant risks inherent in drug development, including clinical trial failures and regulatory hurdles, and limited financial resources compared to large competitors. Success hinges on successful clinical progression and securing further funding.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Industry research reports
- Financial news outlets
Disclaimers:
This information is for informational purposes only and does not constitute financial advice. Investment in clinical-stage biopharmaceutical companies carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ZyVersa Therapeutics Inc.
Exchange NASDAQ | Headquaters Weston, FL, United States | ||
IPO Launch date 2022-12-12 | Co-Founder, Chairman, CEO & President Mr. Stephen C. Glover | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | Website https://www.zyversa.com |
Full time employees 7 | Website https://www.zyversa.com | ||
ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company that develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial for the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. The company has a license agreement with L&F Research LLC, and InflamaCORE, LLC. ZyVersa Therapeutics, Inc. was founded in 2014 and is based in Weston, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.